Find Therapeutics Begins Phase 1 Trial Dosing for FTX-101

MONTREAL, Oct. 21, 2024: Find Therapeutics Inc., a biopharmaceutical company at the clinical stage focusing on developing innovative therapies for autoimmune diseases, has announced the commencement of dosing in a Phase 1 clinical trial for its drug FTX-101 in healthy participants. FTX-101 is a pioneering therapeutic peptide designed to interact with the Plexin A1 and Neuropilin 1 receptor complex in the brain, aiming to enhance remyelination. After this Phase 1 trial, Find Therapeutics intends to evaluate FTX-101 for treating individuals with Chronic Optic Neuropathy—a severe condition caused by demyelination in the visual pathways of the brain and optic nerve, significantly impairing vision.

The Phase 1 trial, the first to involve human subjects, will measure the safety, tolerability, and pharmacokinetics of FTX-101 when administered to healthy individuals. The study's initiation follows authorization from the US Food and Drug Administration earlier this year. The trial includes two segments: Part 1, a randomized, double-blind, placebo-controlled, single ascending dose (SAD) study involving 40 participants; and Part 2, a randomized, double-blind, placebo-controlled, multiple ascending dose (MAD) study with 24 participants.

Philippe Douville, CEO of Find Therapeutics, remarked, "Starting this study is a crucial achievement for both our company and those suffering from Chronic Optic Neuropathy. Through this study, we aim to build on extensive preclinical evidence showcasing FTX-101's impact in autoimmune disease models. A therapy of this nature could significantly advance the treatment of Chronic Optic Neuropathy, potentially becoming the first to improve the lives of those affected by the condition. We anticipate sharing the study's data in the first half of 2025."

FTX-101 represents Find Therapeutics' leading compound, designed specifically to act as a remyelinating agent with the potential to restore vision in those afflicted with Chronic Optic Neuropathy. This therapeutic peptide is engineered to target the Plexin A1 and Neuropilin 1 receptor complex in the brain, which plays a role in activating oligodendrocyte precursor cells to become myelinating oligodendrocytes. Preclinical studies for FTX-101 have shown significant activity in repairing myelin in demyelinating models.

Find Therapeutics is a clinical-stage biopharmaceutical entity committed to creating next-generation therapies for treating inflammatory autoimmune diseases. Founded in 2020, the company receives investment support from CTI Life Sciences, adMare BioInnovations, Domain Therapeutics, and Investissement Québec, and holds an exclusive license from SATT-Conectus and the University of Strasbourg for its technology and associated expertise.